President and CEO David Zaccardelli of Verona Pharma PLC (VRNA, Financial) executed a sale of 141,032 shares of the company on November 4, 2024, according to a recent SEC Filing. Following this transaction, the insider now owns 15,204,752 shares of the company.
Verona Pharma PLC is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for respiratory diseases. The company's focus is on products that are designed to help patients with conditions such as chronic obstructive pulmonary disease (COPD) and cystic fibrosis.
Over the past year, David Zaccardelli has sold a total of 1,800,000 shares and has not made any purchases of the company's stock. This recent transaction is part of a broader trend observed at Verona Pharma PLC, where there have been 12 insider sells and 3 insider buys over the past year.
Shares of Verona Pharma PLC were trading at $4.39 on the day of the transaction, giving the company a market cap of approximately $3.14 billion. This valuation reflects the company's position in the market and its potential for growth in the biopharmaceutical sector.
The company's valuation metrics, such as the price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, are essential for investors to consider when evaluating the stock.
The insider transaction trends at Verona Pharma PLC can be visualized in the following chart, which shows the pattern of buys and sells over the past year:
This insider activity can provide investors with insights into the sentiment of key executives and stakeholders within the company, potentially influencing investment decisions.
For more detailed information on the valuation and insider transactions at Verona Pharma PLC, investors are encouraged to review the GF Value and historical trading data.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
